<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940559</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-006</org_study_id>
    <secondary_id>ACTRN12616001017415</secondary_id>
    <nct_id>NCT04940559</nct_id>
  </id_info>
  <brief_title>Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants</brief_title>
  <official_title>A Phase 1 Study To Determine The Relative Bioavailability Of ACH-0144471 After Administration Of A Tablet Or Softgel Capsule Versus A Liquid Filled Capsule In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, crossover, open-label study to assess the relative bioavailability,&#xD;
      pharmacokinetics (PK), and safety of three different formulations of danicopan (tablet,&#xD;
      softgel capsule, liquid-filled capsule [LFC]) in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2016</start_date>
  <completion_date type="Actual">October 5, 2016</completion_date>
  <primary_completion_date type="Actual">October 5, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Group 1 followed a 3-treatment, 3-period crossover study design. Group 2 followed a 2-treatment, 2-period crossover study design.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK: Maximum Plasma Concentration (Cmax) Of Danicopan After Treatment With Each Of The Three Formulations</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Time To Reach The Maximum Plasma Concentration (Tmax) Of Danicopan After Treatment With Each Of The Three Formulations</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under The Plasma Concentration-time Curve Extrapolated To Infinity (AUC0-Inf) Of Danicopan After Treatment With Each Of The Three Formulations</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax Of Danicopan After Treatment With The Tablet Under Fed And Fasted Conditions</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Tmax Of Danicopan After Treatment With The Tablet Under Fed And Fasted Conditions</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC0-inf Of Danicopan After Treatment With The Tablet Under Fed And Fasted Conditions</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Of Serious Adverse Events, Grade 3 Or 4 Adverse Events (AEs), And AEs Leading To Discontinuation</measure>
    <time_frame>Day 1 through Day 39</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1: Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:&#xD;
Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 3: Danicopan as a tablet under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:&#xD;
Period 1: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 2: Danicopan as a tablet under fasted conditions. Period 3: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:&#xD;
Period 1: Danicopan as a tablet under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. Period 3: Danicopan as a tablet under fed (medium-fat meal) conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received danicopan once each period as a single dose under fasted conditions as follows:&#xD;
Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a softgel capsule under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received danicopan once each period as a single dose under fasted conditions as follows:&#xD;
Period 1: Danicopan as a softgel capsule under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan - Tablet</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Group 1: Sequence 1</arm_group_label>
    <arm_group_label>Group 1: Sequence 2</arm_group_label>
    <arm_group_label>Group 1: Sequence 3</arm_group_label>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-0144471 (formerly)</other_name>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan - Softgel</intervention_name>
    <description>Oral softgel capsule.</description>
    <arm_group_label>Group 2: Sequence 1</arm_group_label>
    <arm_group_label>Group 2: Sequence 2</arm_group_label>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-0144471 (formerly)</other_name>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan - LFC</intervention_name>
    <description>Oral LFC.</description>
    <arm_group_label>Group 1: Sequence 1</arm_group_label>
    <arm_group_label>Group 1: Sequence 2</arm_group_label>
    <arm_group_label>Group 1: Sequence 3</arm_group_label>
    <arm_group_label>Group 2: Sequence 1</arm_group_label>
    <arm_group_label>Group 2: Sequence 2</arm_group_label>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-0144471 (formerly)</other_name>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy was defined as having no clinically relevant abnormalities identified by a&#xD;
             detailed medical history, physical examination, blood pressure and heart rate&#xD;
             measurements, 12-lead electrocardiogram, and clinical laboratory tests.&#xD;
&#xD;
          -  Had a body mass index of 18 to 30 kilograms(kg)/meter squared with a minimum body&#xD;
             weight of 50 kg.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History or clinically relevant evidence of significant cardiovascular, pulmonary,&#xD;
             hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurological, or psychiatric disease.&#xD;
&#xD;
          -  History of procedures that could alter absorption of orally administered drugs.&#xD;
&#xD;
          -  Body temperature ≥ 38°Celsius on Day -1 or Day 1 predose; history of febrile illness&#xD;
             within 7 days prior to study drug administration.&#xD;
&#xD;
          -  Positive alcohol and/or drug screen at Screening or Day -1; current tobacco/nicotine&#xD;
             user.&#xD;
&#xD;
          -  Participation in a clinical study within 30 days prior to study drug administration.&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities at Screening or Day -1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Danicopan</keyword>
  <keyword>ALXN2040</keyword>
  <keyword>ACH-0144471</keyword>
  <keyword>Relative Bioavailability</keyword>
  <keyword>LFC</keyword>
  <keyword>Tablet</keyword>
  <keyword>Softgel Capsule</keyword>
  <keyword>Food Effect</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

